

Clinical trials of bivalirudin + GP2b3a inhibitors

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
bivalirudin + GP2b3a inhibitors vs heparin + GP2b3a inhibitors			
ACUITY (biva+aGP2b3a vs hep+aGP2b3a) , 2006 [NCT00093158] n=4604/4603 follow-up: 30 days	bivalirudin plus a glycoprotein IIb/IIIa inhibitor versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor	in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy.	double blind 17 countries worldwide
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) import , 2007 n=2609/2561 follow-up: 30 days	bivalirudin + versus heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors	patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography.	open

More details and results :

- antithrombotics for acute coronary syndrome in patients managed with an early invasive strategy at <http://www.trialresultscenter.org/go-Q347>
- antithrombotics for acute coronary syndrome in PCI sub group at <http://www.trialresultscenter.org/go-Q348>

References

ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006:

Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007 Dec 5;298:2497-506 [18056903]

ACUITY (sub groups PCI, bivalirudin +aGP2b3a) import, 2007:

Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, , Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19. [17368152] [10.1016/S0140-6736\(07\)60450-4](https://doi.org/10.1016/S0140-6736(07)60450-4)

Entry terms: bivalirudin, Hirulog-1 Hirulog Angiomax